Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

The biology of VEGF and its receptors

Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Met, metastasis, motility and more

Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517

Active and Inactive Protein Kinases: Structural Basis for Regulation

Johnson, L. N., Noble, M. E. M., & Owen, D. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81092-2 · Cited by 1,396

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192

Drug development of MET inhibitors: targeting oncogene addiction and expedience

Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 832

Targeting MET in cancer: rationale and progress

Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3205 · Cited by 1,420

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Yakes, F. M., Chen, J., Tan, J., Yamaguchi, T., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,350

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224

The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules

Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,056

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923

Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway

Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530

MET is required for the recruitment of anti-tumoural neutrophils

Finisguerra, V., Conza, G. D., Matteo, M. D., Serneels, J., Costa, S., Thompson, A. A. R., Wauters, E., Walmsley, S. R., Prenen, H., Granot, Z., et al. (2015) · Nature · doi:10.1038/nature14407 · Cited by 494

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 507

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Choueiri, T. K., Vaishampayan, U. N., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3383 · Cited by 462

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

Sennino, B., Ishiguro‐Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V. J., Tabruyn, S. P., You, W., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 404

c-MET as a potential therapeutic target and biomarker in cancer

Sierra, J. R., & Tsao, M. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422557 · Cited by 367

Phenotypic drug discovery: recent successes, lessons learned and new directions

Vincent, F., Nueda, A., Lee, J. L. C., Schenone, M., Prunotto, M., & Mercola, M. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 397

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics

Okamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00183 · Cited by 328

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2791 · Cited by 307

KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space

van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 310

MET: a promising anticancer therapeutic target

Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

You, W., Sennino, B., Williamson, C. W., Falcón, B. L., Hashizume, H., Yao, L., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 262

Cytokine networking of innate immunity cells: a potential target of therapy

Střı́ž, I., Brabcová, E., Kolesár, L., & Sekerková, A. (2014) · Clinical Science · doi:10.1042/cs20130497 · Cited by 231

Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress

Cui, J. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401427c · Cited by 216

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Shah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Höchster, H. S., Ford, J. M., Kunz, P. L., Lee, F.-C., Kallender, H., Cecchi, F., Rabe, D. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054014 · Cited by 211

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

Myers, S. H., Brunton, V. G., & Unciti‐Broceta, A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01273 · Cited by 213

MSP–RON signalling in cancer: pathogenesis and therapeutic potential

Yao, H., Zhou, Y.-Q., Zhang, R., & Wang, M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3545 · Cited by 205

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H. N., Cancilla, B., Chu, F., Hitchcock‐Bryan, S., Sherman, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 199

The clinical and functional significance of c-Met in breast cancer: a review

Ho-Yen, C., Jones, J. L., & Kermorgant, S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0547-6 · Cited by 197

Anoikis and EMT: Lethal "Liaisons" during Cancer Progression

Cao, Z., Livas, T., & Kyprianou, N. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2016016955 · Cited by 191

Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors

Musumeci, F., Radi, M., Brullo, C., & Schenone, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301085w · Cited by 186

Systemic treatment of renal cell cancer: A comprehensive review

Sánchez-Gastaldo, A., Kempf, E., del Alba, A. G., & Durán, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.010 · Cited by 178

Receptor Tyrosine Kinase Coactivation Networks in Cancer

Xu, A. M., & Huang, P. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0163 · Cited by 176

Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta

Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157

Recent advances in the discovery of small molecule c-Met Kinase inhibitors

Parikh, P. K., & Ghate, M. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.044 · Cited by 157

Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy

Soltan, O. M., Shoman, M. E., Abdel‐Aziz, S. A., Narumi, A., Konno, H., & Abdel‐Aziz, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113768 · Cited by 150

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Jia, H., Dai, G., Weng, J., Zhang, Z., Wang, Q., Zhou, F., Jiao, L., Cui, Y., Ren, Y., Fan, S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500510f · Cited by 144

Papillary renal cell carcinoma: A review of the current therapeutic landscape

Courthod, G., Tucci, M., Maïo, M. D., & Scagliotti, G. V. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.008 · Cited by 141

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer

Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 144

A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients

Tiedt, R., Degenkolbe, E., Furet, P., Appleton, B. A., Wagner, S., Schoepfer, J. G., Buck, E., Ruddy, D. A., Monahan, J. E., Jones, M. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4433 · Cited by 138

Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy

Riquelme, I., Saavedra, K., Espinoza, J. A., Weber, H. L., García, P., Nervi, B., Marcelo Garrido, S., Corvalán, A. H., Roa, J. C., & Bizama, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4990 · Cited by 140

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

Liu, X., Zhao, H.-C., Hou, S.-J., Zhang, H., Cheng, L., Yuan, S., Zhang, L., Song, J., Zhang, S., & Chen, S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106425 · Cited by 137

Kinase Inhibitors of Marine Origin

Bharate, S. B., Sawant, S. D., Singh, P. P., & Vishwakarma, R. A. (2013) · Chemical Reviews · doi:10.1021/cr300410v · Cited by 132

Molecularly targeted therapy in hepatocellular carcinoma

Huynh, H. T. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.034 · Cited by 127

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

Kataoka, Y., Mukohara, T., Tomioka, H., Funakoshi, Y., Kiyota, N., Fujiwara, Y., Yashiro, M., Hirakawa, K., Hirai, M., & Minami, H. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9699-0 · Cited by 118

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

Davare, M. A., Saborowski, A. L., Eide, C. A., Tognon, C. E., Smith, R. L., Elferich, J., Agarwal, A., Tyner, J. W., Shinde, U. P., Lowe, S. W., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319583110 · Cited by 117

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Davare, M. A., Vellore, N. A., Wagner, J. P., Eide, C. A., Goodman, J. R., Drilon, A. E. D. C., Deininger, M. W., O’Hare, T., & Druker, B. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515281112 · Cited by 117

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

Patwardhan, P. P., Ivy, K. S., Musi, E., de Stanchina, E., & Schwartz, G. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6547 · Cited by 116

Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis

Zillhardt, M., Park, S.-M., Romero, I. L., Sawada, K., MONTAG, A. G., Krausz, T. N., Yamada, S. D., Peter, M. E., & Lengyel, E. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3387 · Cited by 116

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors

Smyth, E. C., Sclafani, F., & Cunningham, D. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s44941 · Cited by 115

Immunologically augmented cancer treatment using modern radiotherapy

Durante, M., Reppingen, N., & Held, K. D. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.007 · Cited by 113

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

Fuse, M. J., Okada, K., Oh‐hara, T., Ogura, H., Fujita, N., & Katayama, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0909 · Cited by 112

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

Park, I., Mishra, A., Chandler, J. C., Whitman, S. P., Marcucci, G., & Caligiuri, M. A. (2013) · Blood · doi:10.1182/blood-2012-07-444018 · Cited by 109

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

Cui, J. J., McTigue, M. A., Nambu, M. D., Tran‐Dubé, M., Pairish, M., Shen, H., Jia, L., Cheng, H., Hoffman, J. E., Le, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300967g · Cited by 108

HGF/c-MET Signaling in Melanocytes and Melanoma

Czyż, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123844 · Cited by 99

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs

Zhang, J. C., Jiang, X., Jiang, Y., Guo, M., Zhang, S., Li, J., He, J., Liu, J., Wang, J., & Ouyang, L. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.016 · Cited by 98

MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer

Feng, Y., Thiagarajan, P. S., & Ma, P. C. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182417e44 · Cited by 93

Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine

Holbrook, J. D., Parker, J. S., Gallagher, K. T., Halsey, W. S., Hughes, A. M., Weigman, V., Lebowitz, P. F., & Kumar, R. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-119 · Cited by 94

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Seiwert, T. Y., Sarantopoulos, J., Kallender, H., McCallum, S. W., Keer, H. N., & Blumenschein, G. R. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9861-3 · Cited by 92

Turning liabilities into opportunities: Off-target based drug repurposing in cancer

Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 96

Progress in cancer therapy targeting c-Met signaling pathway

Jung, K. H., Park, B. H., & Hong, S. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0402-6 · Cited by 92

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches

Choi, H. J., Armaiz-Peña, G. N., Pradeep, S., Cho, M. S., Coleman, R. L., & Sood, A. K. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9538-9 · Cited by 92

Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways

Martorana, A., Monica, G. L., & Lauria, A. (2020) · Molecules · doi:10.3390/molecules25184279 · Cited by 92

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead

Soltantoyeh, T., Akbari, B., Karimi, A., Chalbatani, G. M., Ghahri-Saremi, N., Hadjati, J., Hamblin, M. R., & Mirzaei, H. R. (2021) · Cells · doi:10.3390/cells10061450 · Cited by 89

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

Feneyrolles, C., Spenlinhauer, A., Guiet, L., Fauvel, B., Daydé-Cazals, B., Warnault, P., Chevé, G., & Yasri, A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1083 · Cited by 83

Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling

Furlan, A., Colombo, F., Kövér, A., Issaly, N., Tintori, C., Angeli, L., Leroux, V., Letard, S., Amat, M., Asses, Y., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.051 · Cited by 86

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

Varkaris, A. S., Corn, P. G., Gaur, S., Dayyani, F., Logothetis, C. J., & Gallick, G. E. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.631523 · Cited by 80

Structure-Based Design of Novel Class II c-Met Inhibitors: 2. SAR and Kinase Selectivity Profiles of the Pyrazolone Series

Liu, L., Norman, M. H., Lee, M., Xi, N., Siegmund, A., Boezio, A. A., Booker, S. K., Choquette, D., D’Angelo, N. D., Germain, J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201331s · Cited by 79

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma

Demková, L., & Kučerová, L. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0795-z · Cited by 79

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Nelson-Taylor, S. K., Le, A. T., Yoo, M., Schubert, L., Mishall, K. M., Doak, A. E., Varella‐Garcia, M., Tan, A. C., & Doebele, R. C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0008 · Cited by 79

Targeting the MET gene for the treatment of non-small-cell lung cancer

Gelsomino, F., Facchinetti, F., Haspinger, E. R., Garassino, M. C., Trusolino, L., de Braud, F., & Tiseo, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.006 · Cited by 77

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

Appleman, L. J., Parikh, R. A., Wang, P., Beumer, J. H., & Chu, E. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s40241 · Cited by 75

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

Liu, L., Shi, H., Liu, Y., Anderson, A. E., Peterson, J. J., Greger, J., Martin, A., & Gilmer, T. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0698 · Cited by 74

Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety

Li, S., Huang, Q., Liu, Y., Zhang, X., Liu, S., He, C., & Gong, P. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.04.001 · Cited by 74

c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer

Delitto, D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8458 · Cited by 72

Axl inhibitors as novel cancer therapeutic agents

Shen, Y., Chen, X., He, J., Liao, D., & Zu, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.02.033 · Cited by 72

MET molecular mechanisms and therapies in lung cancer

Lawrence, R. E., & Salgia, R. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.10973 · Cited by 70

AXL is an oncotarget in human colorectal cancer

Martinelli, E., Martini, G., Cardone, C., Troiani, T., Liguori, G., Vitagliano, D., Napolitano, S., Morgillo, F., Rinaldi, B., Melillo, R. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3962 · Cited by 66

Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment

Rothenberger, N. J., & Stabile, L. P. (2017) · Cancers · doi:10.3390/cancers9040039 · Cited by 66

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors

Collie, G. W., Koh, C. M., O’Neill, D. J., Stubbs, C. J., Khurana, P., Eddershaw, A., Snijder, A., Mauritzson, F., Barlind, L., Dale, I. L., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00276 · Cited by 61

In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

Sharma, N., & Adjei, A. A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011423403 · Cited by 63

MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme

Knubel, K. H., Pernu, B. M., Sufit, A., Nelson, S., Pierce, A. M., & Keating, A. K. (2014) · Oncotarget · doi:10.18632/oncotarget.1793 · Cited by 62

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis

Shojaei, F., Simmons, B. H., Lee, J. H., Lappin, P. B., & Christensen, J. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.026 · Cited by 62

Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancerin vivoby decreasing VEGFR-2/3 and TIE-2 signaling

Chen, H.-M., Tsai, C., & Hung, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3613 · Cited by 61

Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2

Shi, L., Wu, T.-T., Wang, Z., Xue, J., & Xu, Y. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.008 · Cited by 62

Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors

Matsumoto, S., Miyamoto, N., Hirayama, T., Oki, H., Okada, K., Tawada, M., Iwata, H., Nakamura, K., Yamasaki, S., Miki, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.028 · Cited by 60

Personalized therapy for hepatocellular carcinoma: Where are we now?

Chan, S. L., Wong, A. M., Lee, K., Wong, N., & Chan, A. K. C. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.008 · Cited by 59

RON confers lapatinib resistance in HER2-positive breast cancer cells

Wang, Q., Quan, H., Zhao, J., Xie, C., Wang, L., & Lou, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.022 · Cited by 58

Targeting Angiogenesis in Renal Cell Carcinoma

Lainakis, G., & Bamias, A. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908785133132 · Cited by 58

A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity

Choi, H., Kim, Y., Lee, S., & Kim, Y. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0628 · Cited by 58

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Rayson, D., Lupichuk, S., Potvin, K., Dent, S. F., Shenkier, T., Dhesy‐Thind, S., Ellard, S. L., Prady, C. C. M., Salim, M., Farmer, P. L., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3812-1 · Cited by 58

Role of cMET in the Development and Progression of Colorectal Cancer

Pérez-Vargas, J. C. S., Biondani, P., Maggi, C., Gariboldi, M., Gloghini, A., Inno, A., Volpi, C. C., Gualeni, A. V., Bartolomeo, M. D., de Braud, F., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918056 · Cited by 59

Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.

Faria, C., Golbourn, B., Dubuc, A., Remke, M., Diaz, R., Agnihotri, S., Luck, A. J., Sabha, N., Olsen, S., Wu, X.-C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-3629 · Cited by 52

Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs

Heinzlmeir, S., Kudlinzki, D., Sreeramulu, S., Klaeger, S., Gande, S. L., Linhard, V., Wilhelm, M., Qiao, H., Helm, D., Ruprecht, B., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00709 · Cited by 56

Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma

Huynh, H. T., Ong, R., & Soo, K. C. (2011) · Angiogenesis · doi:10.1007/s10456-011-9243-z · Cited by 56

Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma

Harshman, L. C., & Choueiri, T. K. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829e3c9a · Cited by 55

Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models

Ekins, S., Reynolds, R. C., Franzblau, S. G., Wan, B., Freundlich, J. S., & Bunin, B. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063240 · Cited by 57

TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics

Zhong, J., Kim, M., Chaerkady, R., Wu, X., Huang, T., Getnet, D., Mitchell, C. J., Palapetta, S. M., Sharma, J. N., O’Meally, R. N., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.017764 · Cited by 55

Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells

Cheng, P., Phillips, E. S., Kim, S.-H., Taylor, D., Hielscher, T., Puccio, L., Hjelmeland, A. B., Lichter, P., Nakano, I., & Goidts, V. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.03.005 · Cited by 55

Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors

Qi, B., Mi, B., Zhai, X., Xu, Z., Zhang, X., Tian, Z., & Gong, P. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.06.026 · Cited by 54

Cyclohexane-1,3-dione Derivatives as Future Therapeutic Agents for NSCLC: QSAR Modeling, In Silico ADME-Tox Properties, and Structure-Based Drug Designing Approach

Daouı, O., Elkhattabi, S., Bakhouch, M., Belaıdı, S., Bhandare, R. R., SHAIK, A. B., Mali, S. N., & Chtita, S. (2023) · ACS Omega · doi:10.1021/acsomega.2c07585 · Cited by 54

Melatonin prevents human pancreatic carcinoma cell PANC‐1‐induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression

Cui, P., Yu, M., Peng, X., Dong, L., & Yang, Z.-X. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00933.x · Cited by 53

Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib‐resistant lung cancer growth

Jung, S. K., Lee, M., Lim, D. Y., Lee, S., Jeong, C., Kim, J., Lim, T. G., Chen, H., Bode, A. M., Lee, H. J., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22191 · Cited by 53

Caspase inhibitors: a review of recently patented compounds (2013-2015)

Lee, H., Shin, E. A., Lee, J. H., Ahn, D., Kim, C.-G., Kim, J., & Kim, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1378426 · Cited by 53

Abstract 3613: Dual inhibitors against receptor tyrosine kinases c-Met and VEGFR-2 as efficacious antitumor agents in mouse xenograft tumor models

Wang, Q., Lu, W., Xing, X., Chen, M., Liu, Y., Zhao, L., Li, W., & Jiang, S. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3613

A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities

Awazu, Y., Nakamura, K., Mizutani, A., Kakoi, Y., Iwata, H., Yamasaki, S., Miyamoto, N., Imamura, S., Miki, H., & Hori, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1011 · Cited by 28

Inhibition of tumor cell growth, invasion, and metastasis by SIM-89, a novel inhibitor of HGF receptor tyrosine kinases.

Pei, J., Han, B., Shao, M., & Sha, H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e13528

Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment

Liu, X., Koblish, H. K., Wang, Q., Yang, G., Hall, L. M., Wen, X., Marando, C. A., Behshad, E., Wynn, R., Becker-Pasha, M., et al. (2008) · Cancer Research · Cited by 4

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

You, W., Sennino, B., Williamson, C. W., Falcón, B. L., Hashizume, H., Yao, L., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 262